Drug Profile
Sodium phenylbutyrate/ursodoxicoltaurine - Amylyx Pharmaceuticals
Alternative Names: ALBRIOZA; AMX-0035; PB/TURSO; RELYVRIO; Sodium phenylbutyrate/tauroursodeoxycholic acid; Sodium phenylbutyrate/taurursodiol; Tauroursodeoxycholic acid/sodium phenylbutyrate; UrsodoxicoltaurineLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Amylyx Pharmaceuticals
- Class Amines; Antidementias; Antineoplastics; Antivirals; Cholanes; Electrolytes; Gallstone therapies; Hepatoprotectants; Neuroprotectants; Phenylbutyrates; Small molecules; Sulfonic acids
- Mechanism of Action Ammonia scavengers; Histone deacetylase inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Amyotrophic lateral sclerosis
- Phase III Progressive supranuclear palsy
- Phase II Alzheimer's disease; Wolfram syndrome
- No development reported Friedreich's ataxia
Most Recent Events
- 11 Apr 2024 Interim efficacy, adverse events and pharmacokinetics data from the phase I/II HELIOS trial in Wolfram Syndrome released by Amylyx Pharmaceuticals
- 04 Apr 2024 Withdrawn for Amyotrophic lateral sclerosis (In adults) in USA (PO) based on the results from the phase-III PHOENIX trial
- 04 Apr 2024 Withdrawn for Amyotrophic lateral sclerosis in Canada (PO) based on the results from the phase-III PHOENIX trial